文献速递胸部肿瘤

ASCEND-3 最终结果:色瑞替尼一线治疗 ALK 阳性 NSCLC 的疗效与安全性

Final Overall Survival and Other Efficacy and Safety Results From ASCEND-3: Phase II Study of Ceritinib in ALKi-Naive Patients With ALK-Rearranged NSCLC.
PubMed 文献 · J Thorac Oncol · 2019-11-25

ASCEND-3 是一项 II 期单臂研究,评估色瑞替尼在未接受过 ALK 抑制剂、既往至少三线化疗的 ALK 重排 NSCLC 患者中的疗效与安全性。最终分析显示研究者评估的 ORR 为 67.7%,中位 PFS 16.6 个月,中位 OS 51.3 个月,安全性与此前报道一致。

要点

  • 色瑞替尼在 ALKi 初治、多线化疗后 ALK+ NSCLC 中显示持久疗效。
  • 研究者评估 ORR 67.7%,中位 PFS 16.6 个月,中位 OS 51.3 个月。
  • 常见不良事件为腹泻、恶心、呕吐,14.5% 因不良事件停药。

核心结论

  • 色瑞替尼在化疗经治(至少三线)、ALKi 初治的 ALK+ NSCLC 患者中展现出持久且具有临床意义的 OS、PFS 和缓解持续时间。

研究设计与样本

  • II 期、单臂 ASCEND-3 研究,纳入 124 例 ALKi 初治的 ALK 重排 NSCLC 患者,既往至少三线化疗。
  • 患者口服色瑞替尼 750 mg/天(空腹),主要终点为研究者评估的 ORR。

主要发现

  • 研究者评估的 ORR 为 67.7%(95%CI 58.8-75.9),中位 PFS 为 16.6 个月(95%CI 11.0-23.2)。
  • 中位 OS 为 51.3 个月(95%CI 42.7-55.3),中位随访时间 52.1 个月(范围 48.4-60.1)。
  • 最常见不良事件(所有级别,≥60% 患者,全因)为腹泻(85.5%)、恶心(78.2%)和呕吐(71.8%)。
  • 18 例(14.5%)患者因不良事件导致治疗终止,健康相关生活质量在治疗期间得以维持。

关键数值与推荐

  • 研究者评估 ORR 67.7%(95%CI 58.8-75.9),中位 PFS 16.6 个月(95%CI 11.0-23.2),中位 OS 51.3 个月(95%CI 42.7-55.3)。
  • 124 例患者中 49 例(39.5%)有基线脑转移,122 例(98.4%)既往接受过抗肿瘤药物,31 例(25.0%)接受过至少三线方案。

临床怎么用

  • 对于 ALKi 初治、多线化疗后的 ALK+ NSCLC 患者,色瑞替尼可作为有效治疗选择,需关注腹泻、恶心、呕吐等不良事件管理。

局限性

  • 本研究为单臂 II 期研究,无随机对照,结论需在更广泛人群中验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The phase II, single-arm ASCEND-3 study assessed the efficacy and safety of ceritinib in anaplastic lymphoma kinase (ALK) inhibitor (ALKi)-naive patients with ALK-rearranged NSCLC who had received at least three previous lines of chemotherapy. Here, we report the final efficacy and safety results. METHODS: Eligible patients (including those with asymptomatic or neurologically stable brain metastases) received oral ceritinib (750 mg/day, fasted). The primary end point was investigator-assessed overall response rate (ORR). Secondary end points were Blinded Independent Review Committee-assessed ORR; investigator- and Blinded Independent Review Committee-assessed overall intracranial response rate, duration of response, time to response, disease control rate, and progression-free survival (PFS); overall survival (OS); and safety. Exploratory end points included patient-reported outcomes. RESULTS: Of the 124 patients enrolled, 122 (98.4%) had received previous antineoplastic medications (31 patients [25.0%] received at least three regimens), and 49 (39.5%) had baseline brain metastases. The median follow-up time (data cutoff: January 22, 2018) was 52.1 (range, 48.4-60.1) months. The investigator-assessed ORR was 67.7% (95% confidence interval [CI]: 58.8-75.9), and the median PFS was 16.6 months (95% CI: 11.0-23.2). The median OS was 51.3 months (95% CI: 42.7-55.3). Most common adverse events (all grades, ≥60% of patients, all-causality) were diarrhea (85.5%), nausea (78.2%), and vomiting (71.8%). Overall, 18 patients (14.5%) had an adverse event leading to treatment discontinuation. Health-related quality of life was maintained during ceritinib treatment. CONCLUSIONS: Ceritinib exhibited prolonged and clinically meaningful OS, PFS, and duration of response in chemotherapy-pretreated (at least three lines), ALKi-naive patients with ALK+ NSCLC. The safety profile was consistent with that reported in previous studies.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Nishio M, Felip E, Orlov S, et al. Final Overall Survival and Other Efficacy and Safety Results From ASCEND-3: Phase II Study of Ceritinib in ALKi-Naive Patients With ALK-Rearranged NSCLC. J Thorac Oncol. 2019. PMID: 31778798. doi:10.1016/j.jtho.2019.11.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。